Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval
of newer agent like atezolimumab for use in patients with advanced stage urothelial …

Immune checkpoint inhibitors (ICIs) targeting CTLA4 and PD1 constitute a promising class of
cancer treatment but are associated with several immune-related disorders. We here review …

Objective A novel autoimmune central nervous system (CNS) disorder with glial fibrillary
acidic protein (GFAP)‐IgG as biomarker was recently characterized. Here, 102 patients with …

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionised cancer
therapy but frequently cause immune-related adverse events (irAEs). Description of late …